ArticleNature communications2026
Enzyme-responsive peptide dendron nanoassemblies for targeting and eliminating intracellular drug-resistant bacteria.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Certain intracellular pathogens can reside within cells to evade host immune defenses and exhibit high tolerance to antibiotics. Current treatments for intracellular bacterial infections are limited by poor cellular penetration, inadequate targeting of infected sites, and inefficacy against drug-resistant bacteria. Here, peptide dendron nanoassemblies comprising self-assembling regions, cell-penetrating motifs, enzyme-responsive sequences, and targeting ligands are developed to eliminate intracellular drug-resistant bacteria. The peptide dendrons self-assemble into nanoparticles that bind to membrane integrins via targeting sequence. The receptor-ligand interaction triggers a structural transformation into nanofibers for prolonged retention on the membrane surfaced of infected cells. Subsequently, they transform to nanoparticles upon tailored by bacteria-secreted enzyme, facilitating cellular uptake to target and eradicate intracellular drug-resistant bacteria. Self-assembling peptide dendrons further enhance macrophage resistance to infection-induced damage by modulating ferroptosis. The in vivo efficacy of peptide dendron nanoassemblies in removing intracellular drug-resistant bacteria is demonstrated in male mice and piglet infection models. This study provides a promising therapeutic strategy for treating intracellular drug-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.